Broad alliance queries FDA’s suffixes stance

The US Food and Drug Administration (FDA) should clarify its current thinking on whether biosimilars and original biologics should addafour-letter meaningless suffix to the non-proprietary names of their products, according to a broad coalition covering biosimilar developers, health insurers, pharmacy benefit managers (PBMs), retailers, doctors, pharmacists and consumers. “Does this still represent the agency’s current thinking?” the alliance queries in a submission to a docket on facilitating competition and innovation in the biological products marketplace.

The US Food and Drug Administration (FDA) should clarify its current thinking on whether biosimilars and original biologics should addafour-letter meaningless suffix to the non-proprietary names of their products, according to a broad coalition covering biosimilar developers, health insurers, pharmacy benefit managers (PBMs), retailers, doctors, pharmacists and consumers. “Does this still represent the agency’s current thinking?” the alliance queries in a submission to a docket on facilitating competition and innovation in the biological products marketplace.

In a brief submission, the group of almost 30 organisations – which includes the Biosimilars Council within the US Association...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C11

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes

 

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Sawai Outlook Improves But Japanese Generics Continue To Suffer Under NHI Price Cuts

 
• By 

Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

More from Policy & Regulation

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Policy&Regulation-Free: Article with different widgets

Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.